Recent ATOS News
- Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results • GlobeNewswire Inc. • 03/20/2025 01:13:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2025 01:00:07 PM
- Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications • GlobeNewswire Inc. • 03/11/2025 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2025 09:05:08 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/07/2025 09:09:11 PM
- Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care • GlobeNewswire Inc. • 02/05/2025 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2025 02:00:09 PM
- Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. 12,201,591 • GlobeNewswire Inc. • 01/30/2025 01:17:09 PM
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 • GlobeNewswire Inc. • 01/23/2025 01:15:00 PM
- Atossa Therapeutics Applauds U.S. Surgeon General’s Advisory Highlighting Alcohol as a Leading Preventable Cause of Breast Cancer • GlobeNewswire Inc. • 01/06/2025 02:00:00 PM
- Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/12/2024 01:15:00 PM
- Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density • GlobeNewswire Inc. • 12/11/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2024 02:05:08 PM
- Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/10/2024 02:05:00 PM
- Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research • GlobeNewswire Inc. • 12/09/2024 01:15:00 PM
- Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research • GlobeNewswire Inc. • 11/21/2024 01:30:00 PM
- Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 11/20/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/19/2024 09:35:07 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/19/2024 09:30:19 PM
- Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/12/2024 01:30:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 11/08/2024 07:17:17 PM
- Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development • GlobeNewswire Inc. • 11/05/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 11:35:08 AM
- Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results: • GlobeNewswire Inc. • 11/04/2024 11:30:00 AM
- Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 10/31/2024 12:15:00 PM
LaFleur Minerals Provides Update on Beacon Mill Restart, Results of Annual General and Special Meeting, and Swanson Gold Deposit Exploration and Drilling Updates • LFLRF • Mar 21, 2025 9:40 AM
Basanite Industries, Inc. Appoints Michael D. Nelson as Chief Executive Officer • BASA • Mar 21, 2025 9:01 AM
Fifty 1 Labs, Inc. (FITY) Acquires Genetic Networks, Working to Secure Multi-Million Dollar DoD Contracts, and Positions for Rapid Expansion in Biotech Innovation • FITY • Mar 20, 2025 9:00 AM
VAYK Forms Partnership with Airbnb Investing Group to Offer Service Solution • VAYK • Mar 20, 2025 9:00 AM
4Cable TV International, Inc. (CATV) Facilitates Acquisition of Genetic Networks LLC by Fifty 1 Labs, Inc. (FITY), Announces Dividend for CATV Shareholders, and Sets Stage for Transformative Reverse Merger • CATV • Mar 20, 2025 8:30 AM
NUBURU Announces Elimination of 100% of its Long-Term Indebtedness and $5.15 Million Strategic Investment in Supply@ME Capital • BURU • Mar 19, 2025 8:53 AM